Kianse Networks Controling Flavivirus Replication

Kianse Networks 控制黄病毒复制

基本信息

  • 批准号:
    8234067
  • 负责人:
  • 金额:
    $ 64.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-03-01 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

Flaviviruses need and manipulate host cell pathways at every step of their infectious cycle. Since many host cell pathways are controlled by protein kinases, this class of host proteins is intimately involved in modulating flaviviral replication both negatively, ie. by controlling innate immune responses, as well as positively, by inducing a virus-supportive environment. The goal of this sub-project is to identify those kinase-controlled host cell pathways that support the flavivirus life cycle. Our preliminary data show that broad-spectrum protein tyrosine kinase inhibitors prevent flaviviral entry whereas MAP-kinase inhibitors interfere with replication. Moreover, we previously demonstrated that Src-kinase inhibitors block flaviviral egress due to a requirement of the c-yes kinase for this step. To identify both specific inhibitors and specific kinases controlling each step of the viral life cycle we will use a chemical genomics approach. We will employ cellbased, high content screening of kinase-directed small molecule libraries to identify kinase inhibitors interfering with different steps of the Dengue-virus (DENV) life cycle. In secondary screens we will select for compounds with a high selectivity index, broad cell type specificity and activity against other flaviviruses (WNV, JEV, YFV). Active compounds will likely inhibit several related kinases thus minimizing the problem of redundancy of signaling pathways and tissue specific expression. The kinases targeted by a given compound will be identified by combining computational, functional genomics and biochemical approaches. Based on these results we will generate models of kinase networks controlling flavivirus infection and examine thise models experimentally by phosphoproteomics and by targeted gene knockdown. Finally, we will examine the therapeutic potential of kinase-targeted antivirally active compounds by examining selected compounds in vivo using a murine model West-Nile Virus infection. The efficacy, toxicity and bio-availability of kinase-directed compounds will be compared with the in vivo activity of TYT-1 analogs (sultam thioureas) generated in sub-project 3 of this program. At the end of these comprehensive studies, we anticipate to have gained further insights into the interaction of flaviviruses with their host cell, identified novel targets for antviral drugs discovery, and characterized novel small molecule inhibitors that are active against flaviviruses in vitro and in vivo.
黄病毒在其感染周期的每一步都需要并操纵宿主细胞途径。由于许多主机 细胞途径由蛋白激酶控制,这类宿主蛋白密切参与调节细胞内的蛋白质代谢。 黄病毒复制均为阴性,即通过控制先天免疫反应,以及积极的, 诱导病毒支持环境。这个子项目的目标是识别那些激酶控制的 支持黄病毒生命周期的宿主细胞途径。我们的初步数据显示, 蛋白酪氨酸激酶抑制剂阻止黄病毒进入,而MAP-激酶抑制剂干扰 复制的此外,我们先前证明Src激酶抑制剂阻断黄病毒的排出, 这是c-yes激酶对该步骤的要求。鉴定特异性抑制剂和特异性激酶 控制病毒生命周期的每一步,我们将使用化学基因组学方法。我们将采用基于细胞的, 高含量筛选激酶导向的小分子文库以鉴定激酶抑制剂 干扰登革病毒(DENV)生命周期的不同阶段。在二级屏幕中,我们将选择 具有高选择性指数、宽细胞类型特异性和抗其它黄病毒活性的化合物 (WNV,JEV,YFV)。活性化合物可能会抑制几种相关的激酶,从而最大限度地减少 信号通路的冗余和组织特异性表达。给定的靶向激酶 将通过结合计算、功能基因组学和生物化学方法来鉴定化合物。 基于这些结果,我们将生成控制黄病毒感染的激酶网络模型, 通过磷酸化蛋白质组学和靶向基因敲除实验检验这些模型。最后我们 将通过检查选择的激酶靶向抗病毒活性化合物的治疗潜力, 使用鼠模型西尼罗病毒感染在体内测定化合物。有效性、毒性和生物利用度 将激酶导向化合物的体内活性与TYT-1类似物(磺内酰胺硫脲)的体内活性进行比较。 在本项目的子项目3中生成。在这些全面研究结束时,我们预计 进一步了解了黄病毒与其宿主细胞的相互作用,确定了新的靶点, 抗病毒药物的发现,并表征了对黄病毒有活性的新型小分子抑制剂 在体外和体内。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Klaus J Fruh其他文献

Klaus J Fruh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Klaus J Fruh', 18)}}的其他基金

Non-canonical epitope presentation and antigen processing by MHC-E
MHC-E 的非典型表位呈递和抗原加工
  • 批准号:
    10801509
  • 财政年份:
    2023
  • 资助金额:
    $ 64.83万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9982274
  • 财政年份:
    2017
  • 资助金额:
    $ 64.83万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9238234
  • 财政年份:
    2017
  • 资助金额:
    $ 64.83万
  • 项目类别:
A Cytomegalovirus-based Vaccine Targeting the Pre-erythrocytic Stage of Malaria
一种针对疟疾红细胞前阶段的巨细胞病毒疫苗
  • 批准号:
    9751633
  • 财政年份:
    2017
  • 资助金额:
    $ 64.83万
  • 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
  • 批准号:
    8607501
  • 财政年份:
    2013
  • 资助金额:
    $ 64.83万
  • 项目类别:
An Effector Memory T Cell-Inducing Subunit Vaccine against Malaria
一种针对疟疾的效应记忆 T 细胞诱导亚单位疫苗
  • 批准号:
    8423271
  • 财政年份:
    2013
  • 资助金额:
    $ 64.83万
  • 项目类别:
MECHANISMS OF IMMUNE VULNERABILITY OF THE ELDERLY TO THE WEST NILE VIRUS
老年人对西尼罗河病毒免疫脆弱的机制
  • 批准号:
    8357751
  • 财政年份:
    2011
  • 资助金额:
    $ 64.83万
  • 项目类别:
EVASION OF ANTIGEN PRESENTATION BY RHESUS CYTOMEGALOVIRUS
恒河猴巨细胞病毒逃避抗原呈递
  • 批准号:
    8357750
  • 财政年份:
    2011
  • 资助金额:
    $ 64.83万
  • 项目类别:
MODULATION OF INNATE IMMUNE RESPONSES BY CYTOMEGALOVIRUS
巨细胞病毒对先天免疫反应的调节
  • 批准号:
    8357775
  • 财政年份:
    2011
  • 资助金额:
    $ 64.83万
  • 项目类别:
Development and Analysis of Replication-Deficient CMV Vectors
复制缺陷型 CMV 载体的开发和分析
  • 批准号:
    8117930
  • 财政年份:
    2011
  • 资助金额:
    $ 64.83万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 64.83万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 64.83万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 64.83万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 64.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 64.83万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 64.83万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 64.83万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 64.83万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 64.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 64.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了